FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
8 letters match. Newest first.
-
DrugsStream2Sea, LLC
FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.
Medium -
DrugsSignature Formulations, LLC
FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.
High risk -
DrugsSklar Personal Care Inc.
Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.
High risk -
DrugsKaylaan LLC
FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.
High risk -
DrugsMaster Paints & Chemicals Corp.
FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.
High risk -
DrugsFirstCham Co., Ltd.
FDA warns FirstCham over current good manufacturing practice violations and misbranding of Soo'Ae hand sanitizing wipes.
High risk -
DrugsB & J Group
B & J Group, a Morrisville, PA contract filler of OTC hand sanitizer, was cited by FDA for skipping finished-product and ingredient testing.
High risk -
DrugsMcConnell Labs Inc.
McConnell Labs Inc. released hand sanitizers without raw material identity, finished product, or stability testing, FDA says.
High risk